Characteristics of the patients
toxicity, PD
Among all patients of the original phase II study, 16 patients discontinued apatinib due to toxicity intolerance or PD, and furtherly exploratory accepted combination therapy of ATRA (25 mg/mCONSORT flow diagram.We included 16 patients (Table Characteristics of 16 patients before receiving combination therapy of apatinib and ATRA.First‐line TPF Chemotherapy (Docetaxel + Cisplatin + Fluorouracil).First‐line TP Chemotherapy (Paclitaxel + Cisplatin).1st line TP/GP Chemotherapy (Paclitaxel + Cisplatin/Gemcitabine + Cisplatin).